Last reviewed · How we verify
NCT06721507
2024 Tirzepatide-Bariatric Surgery
Phase 4 trial testing tirzepatide in Obesity and Obesity-related Medical Conditions in 50 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Marlene Starr |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 27 March 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- tirzepatide (TIRZEPATIDE) — full drug profile →
- Standard of Care
Conditions studied
- Obesity and Obesity-related Medical Conditions — all drugs for Obesity and Obesity-related Medical Conditions →
- Bariatric Surgery — all drugs for Bariatric Surgery →
Sponsor
Marlene Starr
Who can join
18 and older, any sex, with Obesity and Obesity-related Medical Conditions or Bariatric Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial will test whether preoperative tirzepatide treatment improves outcomes after bariatric surgery. The outcome of this study could impact therapeutic guidelines for the multimodal treatment of obesity. The major objectives are: 1. To evaluate whether pre-operative tirzepatide treatment reduces tissue and circulating inflammatory markers at the time of surgery. 2. To establish the relationship of these changes with postoperative improvements in weight loss, metabolic and inflammatory profiles, comorbidity resolution (glycemic control, blood pressure, lipid profile), and 30-day surgical complications. Researchers will compare data from patients taking tirzepatide to data from patients not taking tirzepatide before their planned bariatric surgery to see if tirzepatide reduces inflammation and improves health outcomes after bariatric surgery. Participants will: Take or not take tirzepatide, depending on what study group they are in, once a week for 3 months. Visit the endocrine clinic once a month for 3 months to be prescribed the drug and for checkups regarding side effects due to the drug. Keep a diary to document taking the drug and any side effects. Continue with their planned bariatric surgery and post-surgery follow-ups according to their healthcare provider.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients With Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial.
Jain V, McMullen CA, Kimbrough JI, Rockich AK, et al · · 2026 · PMID 41643256 · DOI 10.1016/j.jss.2026.01.004
Verify or expand the search:
- PubMed search for NCT06721507
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of tirzepatide
Trials testing the same drug.
- NCT06565611 — A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity · Phase 2 · active not recruiting
- NCT03131687 — A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus · Phase 2 · completed
Other recruiting trials for Obesity and Obesity-related Medical Conditions
Currently open trials in the same condition.
- NCT06924177 — UTSW NORC Pilot Spinal Cord Injury Dietary Program · NA · recruiting
- NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting
- NCT07213245 — Metabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF) · NA · recruiting
- NCT06768827 — New Mechanisms of Obesity · NA · recruiting
- NCT06790225 — Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06721507 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Marlene Starr
- Last refreshed: 5 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06721507.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing